Denali Therapeutics Inc. (DNLI)

NASDAQ • Healthcare

$20

-$0.53 (-2.6%)

Market closed

Last close at October 2, 2026 at 20:00 UTC

Open$20.85

Day Range$19.93 - $20.85

Avg. Volume (3M)1.8M

Market Cap$3.1B

52 Week Range

$13.75$27.3

Next EarningsIn 32 daysNov 5, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$3.6M100%

Gross Profitminus cost of goods$3.5M97%

Fundamentals & Financials

Revenue (TTM)

$3.6M

Net Income (TTM)

-$511.4M

EPS (TTM)

-$2.84

ROA (TTM)

-44.17%

Current Ratio

8.37

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+2.7%Q3 2025-$0.72

+2.6%Q4 2025-$0.74

+2.7%Q1 2026-$0.73

+5.5%Q2 2026-$0.69

-32.5%Q3 2026-$0.68

Nov 5

in 32 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -32.5%

Denali Therapeutics’ earnings trailed consensus as EPS of -$0.68 came in below the -$0.51 estimate (difference -$0.17), in results for the second fiscal quarter of 2026 reported August 6, 2026. Revenue totaled about $3.6 million, with the quarter’s mix also showing roughly $3.5 million of gross profit and a gross margin of ~97%. Operating results remained loss-making, with an operating loss of around $130.5 million, and net income of roughly -$127.6 million, down 2.8% year over year from -$124.1 million a year ago as the clinical-stage biotech continues to fund programs across neurodegenerative and related diseases. Consensus for the next period calls for EPS of -$0.42 on revenue of $12.2 million.

View full earnings history

About Denali Therapeutics Inc.

Denali Therapeutics Inc. is a U.S.-focused biotechnology company listed on NASDAQ as DNLI that develops drug candidates for neurodegenerative and related diseases. In qualitative terms, it is a clinical-stage healthcare business built around advancing targeted therapies, with programs that span Parkinson's disease, ALS, Hunter syndrome, multiple sclerosis, Alzheimer's disease, and cutaneous lupus erythematosus.

Name

Denali Therapeutics Inc.

CEO

Ryan J. Watts

Website

www.denalitherapeutics.com

Industry

Healthcare

Year Founded

2013

Employees

503

Today's Snapshot

AI-generated

DNLI closed 2.6% lower at 20.00, while its sector was flat.

Trading Volume

Below 10d avg (2.0M)

1.6M

vs S&P 500 Today

Strong Underperformance

-3.36%

Updated: October 2, 2026 at 20:17 UTC

Technical Indicators

0 Buy3 Neutral5 Sell

DNLI shows a broadly negative technical posture with price below most short‑ and medium-term moving averages and on-balance volume indicating distribution, while ADX points to a moderate downward trend. Momentum indicators are subdued and MACD is non‑bullish, even as RSI sits near oversold levels and ATR reflects elevated percentage volatility for the share price. The classic pivot is slightly above the market, providing a nearby resistance reference. Technical takeaway: The technical picture favors sellers with price positioned beneath key moving averages.

All signals